FORM PTO-1449 (Modified)

US DEPARTMENT OF COMMERCE

Docket No.

Application No.

Approved for use through 10/31/2002 US Patent and Tradema
INFORMATION DISCLOSURE CITATION

US Patent and Trademark Office

Applicant

10/751,043

in an Application (Use several sheets if necessary)

Syed F.A. Hossainy et al.

Filing Date

50623.362

Group Art Unit

050	<b>E</b>	(555 555 555 555 555 555 555 555 555 55		January 2, 2004	4	1	616
PATRIFIE			U.S. PAT	ENT DOCUMENTS			
Examiner Initial	Ref. No.	Document Number	Date of Patent	Name	Class	Subclass	Filing Date if Appropriate
/KG/	A1	4,329,383	5/11/82	Joh	428	36	, 
	A2	4,733,665	3/29/88	Palmaz	128	343	
	A3	4,800,882	1/31/89	Gianturco	128	343	
	A4	4,882,168	11/21/89	Casey et al.	424	468	•
	A5	4,886,062	12/12/89	Wiktor	128	343	
	A6	4,941,870	7/17/90	Okada et al.	600	36	
	A7	4,977,901	12/18/90	Ofstead	128	772	
	A8	5,112,457	5/12/92	Marchant	204	165	
	A9	5,165,919	11/24/92	Sasaki et al.	424	488	
	A10	5,272,012	12/21/93	Opolski .	428	423.1	
	A11	5,292,516	3/8/94	Viegas et al.	424	423	
	A12	5,298,260	3/29/94	Viegas et al.	424	486	
	A13	5,300,295	4/5/94	Viegas et al.	424	427	
	A14	5,306,501	4/26/94	Viegas et al.	424	423	
	A15	5,328,471	7/12/94	Slepian	604	101	
	A16	5,330,768	7/19/94	Park et al.	424	501	
	A17	5,380,299	1/10/95	Fearnot et al.	604	265	
	A18	5,417,981	5/23/95	Endo et al.	424	486	
	A19	5,447,724	9/5/95	Helmus et al.	424	426	
	A20	5,455,040	10/3/95	Marchant	424	426	
	A21	5,462,990	10/31/95	Hubbell et al.	525	54.1	
	A22	5,464,650	11/7/95	Berg et al.	427	2.30	
	A23	5,569,463	10/29/96	Helmus et al.	424	426	
	A24	5,578,073	11/26/96	Haimovich et al.	623	1	
<b>V</b>	A25	5,605,696	2/25/97	Eury et al.	424	423	
/KG/	A26	5,609,629	3/11/97	Fearnot et al.	623	1	

/KG/	A27	5,624,411	4/29/97	Tuch	604	265	
1	A28	5,628,730	5/13/97	Shapland et al.	604	21	
	A29	5,649,977	7/22/97	Campbell	623	1	
	A30	5,658,995	8/19/97	Kohn et al.	525	432	
	A31	5,667,767	9/16/97	Greff et al.	424	9.411	
	A32	5,670,558	9/23/97	Onishi et al.	523	112	
	A33	5,679,400	10/21/97	Tuch	427	2.14	
	A34	5,700,286	12/23/97	Tartaglia et al.	623	1	
	A35	5,702,754	12/30/97	Zhong	427	2.12	
	A36	5,716,981	2/10/98	Hunter et al.	514	449	
	A37	5,735,897	4/7/98	Buirge	623	12	
	A38	5,746,998	5/5/98	Torchilin et al.	424	9.4	
	A39	5,776,184	7/7/98	. Tuch	623	. 1	
	A40	5,788,979	8/4/98	Alt et al.	424	426	
	A41	5,800,392	9/1/98	Racchini	604	96	
	A42	5,820,917	10/13/98	Tuch	427	2.1	
	A43	5,824,048	10/20/98	Tuch	623	1	
	A44	5,824,049	10/20/98	Ragheb et al.	623	1	
	A45	5,830,178	11/3/98	Jones et al.	604	49	
	A46	5,837,008	11/17/98	Berg et al.	623	- 1	
	A47	5,837,313	11/17/98	Ding et al.	427	2.21	
	A48	5,851,508	12/22/98	Greff et al.	424	9.411	
	A49	5,858,746	1/12/99	Hubbell et al.	435	177	1/25/95
	A50	5,865,814	2/2/99	Tuch	604	265	8/6/97
	A51	5,869,127	2/9/99	Zhong	427	2.12	6/18/97
	A52	5,873,904	2/23/99	Ragheb et al.	623	1	2/24/97
	A53	5,876,433	3/2/99	Lunn	623	1	5/29/96
	A54	5,877,224	3/2/99	Brocchini et al.	514	772.2	7/28/95
	A55	5,925,720	7/20/99	Kataoka et al.	525	523	12/18/97
	A56	5,955,509	9/21/99	Webber et al.	514	772.7	4/23/97
Ψ	A57	5,971,954	10/26/99	Conway et al.	604	96	1/29/97
/KG/	A58	5,980,928	11/9/99	Terry	424	427	7/29/97

/KG/	A59	5,980,972	11/9/99	Ding	427	2.24	9/22/97
	A60	5,997,517	12/7/99	Whitbourne	604	265	1/27/97
	A61	6,010,530	1/4/00	Goicoechea	623	1	2/18/98
	A62	6,015,541	1/18/00	Greff et al.	424	1.25	11/3/97
	A63	6,033,582	3/7/00	Lee et al.	216	37	1/16/98
	A64	6,042,875	3/28/00	Ding et al.	427	2.24	3/2/99
	A65	6,051,648	4/18/00	Rhee et al.	525	54.1	1/13/99
	A66	6,051,576	4/18/00	Ashton et al.	514	255	1/29/97
	A67	6,056,993	5/2/00	Leidner et al.	427	2.25	4/17/98
	A68	6,060,451	5/9/00	DiMaio et al.	514	13	3/20/95
	A69	6,060,518	5/9/00	Kabanov et al.	514	781	8/16/96
	A70	6,080,488	6/27/00	Hostettler et al.	428	423.3	3/24/98
	A71	6,096,070	8/1/00	Ragheb et al.	623	1	5/16/96
	A72	6,099,562	8/8/00	Ding et al.	623	1.46	12/22/97
	A73	6,110,188	8/29/00	Narciso, Jr.	606	153	3/9/98
	A74	6,110,483	8/29/00	Whitbourne et al.	424	423	6/23/97
	A75	6,113,629	9/5/00	Ken	623	1.1	· 5/1/98
	A76	6,120,536	9/19/00	Ding et al.	623	1.43	6/13/96
	A77	6,120,904	9/19/00	Hostettler et al.	428	423.3	5/24/99
	A78	6,121,027	9/19/00	Clapper et al.	435	180	8/15/97
	A79	6,129,761	10/10/00	Hubbell	623	11	6/7/95
	A80	6,153,252	11/28/00	Hossainy et al.	427	2.3	4/19/99
	A81	6,165,212	12/26/00	Dereume et al.	623	1.13	6/28/99
	A82	6,203,551	3/20/01	Wu	606	108	10/4/99
	A83	6,231,600	5/15/01	Zhong	623	1.42	5/26/99
	A84	6,240,616	6/5/01	Yan	29	527.2	4/15/97
	A85	6,245,753	6/12/01	Byun et al.	514	56	4/27/99
	A86	6,251,136	6/26/01	Guruwaiya et al.	. 623	1.46	12/8/99
	A87	6,254,632	7/3/01	Wu et al.	623	1.15	9/28/00
V	A88	6,258,121	7/10/01	Yang et al.	623	1.46	7/2/99
/KG/	A89	6,283,947	9/4/01	Mirzaee	604	264	7/13/99

/KG/	A90	6,283,949	9/4/01	Roorda	604	288.02	12/27/99	
1	A91	6,284,305	9/4/01	Ding et al.	427	2.28	5/18/00	
	A92	6,287,628	9/11/01	Hossainy et al.	427	2.3	9/3/99	
	A93	6,299,604	10/9/01	Ragheb et al.	604	265	8/20/99	
	A94	6,306,176	10/23/01	Whitbourne	623 23.59		9/21/99	
	A95	6,331,313	12/18/01	Wong et al.	424 427 10		10/22/99	
	A96	6,335,029	1/1/02	Kamath et al.	424 423		12/3/98	
	A97	6,346,110	2/12/02	Wu	606	108	1/3/01	
	A98	6,358,556	3/19/02	Ding et al.	427	2.24	1/23/98	
	A99	6,379,381	4/30/02	Hossainy et al.	623	1.42	9/3/99	
	A100	6,395,326	5/28/02	Castro et al.	427	2.24	5/31/00	
	A101	6,419,692	7/16/02	Yang et al.	623	1.15	2/3/99	
	A102	6,451,373	9/17/02	Hossainy et al.	427	2.25	8/4/00	
	A103	6,494,862	12/17/02	Ray et al.	604	96.01	12/30/99	
	A104	6,503,556	1/7/03	Harish et al.	427	2.24	12/28/00	
	A105	6,503,954	1/7/03	Bhat et al.	514	772.2	7/21/00	
	A106	6,506,437	1/14/03	Harish et al.	427	2.25	10/17/00	
	A107	6,527,801	3/4/03	Dutta	623	1.46	4/13/00	
	A108	6,527,863	3/4/03	Pacetti et al.	118	500	6/29/01	
	A109	6,540,776	4/1/03	Sanders Millare et al.	623	1.15	12/28/00	
	A110	6,544,223	4/8/03	Kokish	604	103.01	1/5/01	
	A111	6,544,543	4/8/03	Mandrusov et al.	424	422	12/27/00	
	A112	6,544,582	4/8/03	Yoe	427	2.24	1/5/01	
$\top$	A113	6,555,157	4/29/03	Hossainy	427	2.24	7/25/00	
	A114	6,558,733	5/6/03	Hossainy et al.	427	2.24	10/26/00	
	A115	6,565,659	5/20/03	Pacetti et al.	118	500	6/28/01	
	A116	6,572,644	6/3/03	Moein	623	1.11	6/27/01	
$\forall$	A117	6,585,765	7/1/03	Hossainy et al.	623	1.45	6/29/00	
/KG/	A118	6,585,926	7/1/03	Mirzaee	264	400	8/31/00	

/KG/	A119	6,605,154	8/12/03	Villareal	118	500	5/31	/01
		U.S. PATE	NT APPLICAT	ION PUBLICATION DOCUM	MENTS			
Examiner Initial	Ref. No.	Document Number	Date of Publication	Name	Class	Subclass	Filing ( Appro	
/KG/	A120	2001/0018469	8/30/01	Chen et al.	523	121	12/2	8/00
	A121	2001/0037145	11/1/01	Guruwaiya et al.	623.	1.15	6/21	/01
	A122	2002/0077693	6/20/02	Barclay et al.	623	1.13	12/1	9/00
	A123	2002/0091433	7/11/02	Ding et al.	623	1.2	12/1	7/01
	A124	2002/0155212	10/24/02	Hossainy	427	2.25	4/24	/01
V	A125	2003/0065377	4/3/03	Davila et al.	623	1.13	4/30	)/02
/KG/	A126	2003/0099712	5/29/03	Jayaraman	424	486	11/26/01	
			FOREIGN PA	ATENT DOCUMENTS	· · · · · · · · · · · · · · · · · · ·			
Examiner Initial	Ref. No.	Document Number	Date of Publication	Country	Class	Subclass	Transi Yes	ation No
/KG/	B1	EP 0 301 856	2/1/89	EPO				
1_	B2	EP 0 514 406	11/25/92	EPO				
	В3	EP 0 604 022	6/29/94	EPO				
	B4	EP 0 623 354	11/9/94	EPO				
	B5	EP 0 665 023	8/2/95	EPO				
	B6	EP 0 701 802	3/20/96	EPO				
	В7	EP 0 716 836	6/19/96	EPO				
	В8	EP 0 809 999	12/3/97	EPO				_
	В9	EP 0 832 655	4/1/98	EPO				
	B10	EP 0 850 651	7/1/98	EPO				
•	B11	EP 0 879 595	11/25/98	EPO				
	B12	EP 0 910 584	4/28/99	EPO	1			
	B13	EP 0 923 953 .	6/23/99	EPO				
	B14	EP 0 953 320	11/3/99	EPO				
	B15	EP 0 970 711	1/12/00	EPO				
	B16	EP 0 982 041	3/1/00	EPO				
	B17	EP 1 273 314	1/8/03	EPO				
	B18	2001-190687	7/17/01	Japan (Abstract)			х	
V	B19	WO 91/12846	9/5/91	WIPO				
/KG/	B20	WO 95/10989	4/27/95	WIPO				

/KG/	B21	WO 96/40174	12/19/96	WIPO	T			
	B22	WO 97/10011	3/20/97	WIPO				
	B23	WO 97/45105	12/4/97	WIPO				
1	B24	WO 97/46590	12/11/97	WIPO			1	
	B25	WO 98/17331	4/30/98	WIPO				
	B26	WO 98/36784	8/27/98	WIPO				
	B27	WO 99/01118	1/14/99	WIPO				
	B28	WO 99/38546	8/5/99	WIPO				
	B29	WO 99/63981	12/16/99	WIPO				
	B30	WO 00/02599	1/20/00	WIPO				
	B31	WO 00/12147	3/9/00	WIPO				
	B32	WO 00/18446	4/6/00	WIPO				
	B33	WO 00/64506	11/2/00	WIPO				
	B34	WO 01/01890	1/11/01	WIPO				
	B35	WO 01/15751	3/8/01	WIPO				
	B36	WO 01/17577	3/15/01	WIPO				
	B37	WO 01/45763	6/28/01	WIPO				
	B38	WO 01/49338	7/12/01	WIPO				
	B39	WO 01/74414	10/11/01	WIPO				
	B40	WO 02/03890	1/17/02	WIPO				
	B41	WO 02/026162	4/4/02	WIPO				
	B42	WO 02/34311	5/2/02	WIPO				
	B43	WO 02/056790	7/25/02	WIPO				
	B44	WO 03/000308	1/3/03	WIPO				
	B45	WO 03/022323	3/20/03	WIPO				
	B46	WO 03/028780	4/10/03	WIPO				
Ψ	B47	WO 03/037223	5/8/03	WIPO				
KG/	B48	WO 03/039612	5/15/03	WIPO				
		OTHER DO	CUMENTS (Inc	luding Author, Title, Date, Pertinent P	ages, etc.	.)		
/KG/	C1			the Dream Stent, Clinica 710:15 (J				
/KG/	C2			complications by 30%, Clinica 73 ht?req=1061847871753, printed 8			96),	

/KG/	C3	Anonymous, Rolling Therapeutic Agent Loading Device for Therapeutic Agent Delivery or Coated Stent (Abstract 434009), Res. Disclos. pp. 974-975 (June 2000).
	C4	Anonymous, Stenting continues to dominate cardiology, Clinica 720:22 (Sept. 2, 1996), http://www.dialogweb.com/cgi/document?req=1061848017752, printed 8/25/03 (2 pages).
	C5	Aoyagi et al., Preparation of cross-linked aliphatic polyester and application to thermo-responsive material Journal of Controlled Release 32:87-96 (1994).
	C6	Barath et al., Low Dose of Antitumor Agents Prevents Smooth Muscle Cell Proliferation After Endothelial Injury, JACC 13(2): 252A (Abstract) (Feb. 1989).
	C7	Barbucci et al., Coating of commercially available materials with a new heparinizable material, J. Biomed. Mater. Res. 25:1259-1274 (Oct. 1991).
	C8	Chung et al., Inner core segment design for drug delivery control of thermo-responsive polymeric micelles Journal of Controlled Release 65:93-103 (2000).
	C9	Dev et al., Kinetics of Drug Delivery to the Arterial Wall Via Polyurethane-Coated Removable Nitinol Sten Comparative Study of Two Drugs, Catheterization and Cardiovascular Diagnosis 34:272-278 (1995).
	C10	Dichek et al., Seeding of Intravascular Stents with Genetically Engineered Endothelial Cells, Circ. 80(5):1347-1353 (Nov. 1989).
ŀ	C11	Eigler et al., Local Arterial Wall Drug Delivery from a Polymer Coated Removable Metallic Stent: Kinetics, Distribution, and Bioactivity of Forskolin, JACC, 4A (701-1), Abstract (Feb. 1994).
	C12	Helmus, Overview of Biomedical Materials, MRS Bulletin, pp. 33-38 (Sept. 1991).
	C13	Herdeg et al., Antiproliferative Stent Coatings: Taxol and Related Compounds, Semin. Intervent. Cardiol. 3:197-199 (1998).
	C14	Inoue et al., An AB block copolymer of oligo(methyl methacrylate) and poly(acrylic acid) for micellar delivery of hydrophobic drugs, Journal of Controlled Release 51:221-229 (1998).
	C15	Kataoka et al., Block copolymer micelles as vehicles for drug delivery, Journal of Controlled Release 24:119-132 (1993).
	C16	Levy et al., Strategies For Treating Arterial Restenosis Using Polymeric Controlled Release Implants, Biotechnol. Bioact. Polym. [Proc. Am. Chem. Soc. Symp.], pp. 259-268 (1994).
	C17	Liu et al., <i>Drug release characteristics of unimolecular polymeric micelles</i> , Journal of Controlled Release 68:167-174 (2000).
	C18	Marconi et al., Covalent bonding of heparin to a vinyl copolymer for biomedical applications, Biomaterials 18(12):885-890 (1997).
	C19	Matsumaru et al., Embolic Materials For Endovascular Treatment of Cerebral Lesions, J. Biomater. Sci. Polymer Edn 8(7):555-569 (1997).
	C20	Miyazaki et al., Antitumor Effect of Implanted Ethylene-Vinyl Alcohol Copolymer Matrices Containing Anticancer Agents on Ehrlich Ascites Carcinoma and P388 Leukemia in Mice, Chem. Pharm. Bull. 33(6) 2490-2498 (1985).
	C21	Miyazawa et al., Effects of Pemirolast and Tranilast on Intimal Thickening After Arterial Injury in the Rat, Cardiovasc. Pharmacol., pp. 157-162 (1997).
	C22	Nordrehaug et al., A novel biocompatible coating applied to coronary stents, EPO Heart Journal 14, p. 32 (P1694), Abstr. Suppl. (1993).
	C23	Ohsawa et al., Preventive Effects of an Antiallergic Drug, Pemirolast Potassium, on Restenosis After Percutaneous Transluminal Coronary Angioplasty, American Heart Journal 136(6):1081-1087 (Dec. 1998)
V	C24	Ozaki et al., New Stent Technologies, Progress in Cardiovascular Diseases, Vol. XXXIX(2):129-140 (Sept./Oct. 1996).
/KG/	C25	Pechar et al., Poly(ethylene glycol) Multiblock Copolymer as a Carrier of Anti-Cancer Drug Doxorubicin, Bioconjucate Chemistry 11(2):131-139 (Mar./Apr. 2000).

Shigeno <i>Prevention of Cerebrovas</i>				
Abstract 125:212307 (1996).	cular Spasm By Bosen	tan, Novel Endothelin Receptor, Chemical		
van Beusekom et al., Coronary ster	nt coatings, Coronary A	rtery Disease 5(7):590-596 (July 1994).		
Wilensky et al., Methods and Devices for Local Drug Delivery in Coronary and Peripheral Arteries, Trends Cardiovasc. Med. 3(5):163-170 (1993).				
polymeric micelles and their design	of physical entrapment of for in vivo delivery to a	and chemical conjugation of adriamycin in solid tumor, Journal of Controlled Release		
nata George/	DATE CONSIDERED	03/11/2007		
	van Beusekom et al., Coronary ster Wilensky et al., Methods and Devic Cardiovasc. Med. 3(5):163-170 (19 Yokoyama et al., Characterization o	van Beusekom et al., Coronary stent coatings, Coronary A Wilensky et al., Methods and Devices for Local Drug Deliv Cardiovasc. Med. 3(5):163-170 (1993). Yokoyama et al., Characterization of physical entrapment polymeric micelles and their design for in vivo delivery to a 50:79-92 (1998).		